Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | NDAQ

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
BridgeBio Pharma, Inc. Develops transformative medicines for genetic diseases and genetically driven cancers.	United States of America	BBIO
BRIGHT MINDS BIOSCIENCES INC. Developing next-gen serotonergic drugs for neurological and psychiatric disorders like epilepsy.	United States of America	DRUG
BRISTOL MYERS SQUIBB CO Develops innovative medicines for oncology, immunology, and cardiovascular diseases.	United States of America	BMY
BUKWANG PHARMACEUTICAL IND CO.,LTD R&D pharma firm developing drugs for CNS disorders, oncology, and metabolic diseases.	South Korea	003000
Burning Rock Biotech Ltd Offers NGS-based diagnostics for precision oncology, from detection to clinical trial support.	United States of America	BNR
C4 Therapeutics, Inc. Developing protein degrader medicines to treat cancer and other serious diseases.	United States of America	CCCC
Cabaletta Bio, Inc. Develops engineered T cell therapies for a curative reset in autoimmune diseases.	United States of America	CABA
Cadrenal Therapeutics, Inc. Developing novel anticoagulant therapies for high-risk cardiovascular patients.	United States of America	CVKD
CalciMedica, Inc. Develops CRAC channel inhibitors for critical illnesses like acute pancreatitis & AKI.	United States of America	CALC
Calidi Biotherapeutics, Inc. Develops immunotherapies using stem cells to deliver oncolytic viruses against solid tumors.	United States of America	CLDI